文献速递淋巴瘤造血干细胞移植与细胞治疗

真实世界中Axicabtagene Ciloleucel体内扩增与侵袭性B细胞淋巴瘤治疗结局的关联

Axicabtagene ciloleucel in vivo expansion and treatment outcome in aggressive B-cell lymphoma in a real-world setting.
PubMed 文献 · Blood Adv · 2021-01-01

该前瞻性研究在真实世界中对21例接受axi-cel治疗的侵袭性B细胞淋巴瘤患者进行CAR-T细胞定量监测,中位峰值CAR-T细胞计数为16.14个/µL。

要点

  • 真实世界中axi-cel峰值CAR-T细胞计数≥16.14个/µL与第30天更高客观缓解率相关。
  • 峰值CAR-T细胞≥16.14/µL、血小板正常、无既往移植与更好PFS相关。
  • 调整血小板和移植后,峰值低于中位仍与更短PFS独立相关。

核心结论

  • 真实世界中axi-cel扩增水平与治疗结局相关,并首次用cutoff区分弱扩增者与强扩增者及其结局。

研究设计与样本

  • 前瞻性队列研究,纳入21例在本诊所接受axi-cel治疗的侵袭性B细胞淋巴瘤患者,进行CAR-T细胞定量监测。

主要发现

  • 中位峰值CAR-T细胞计数为16.14个/µL。
  • 低血小板计数对PFS的显著影响持续存在。

临床怎么用

  • 真实世界中可考虑定量监测axi-cel体内扩增,峰值≥16.14个/µL提示强扩增并与更好早期缓解相关。
  • 淋巴清除前血小板计数正常及无既往干细胞移植与更好PFS相关,可辅助风险分层。

局限性

  • 样本量仅21例,结论需更大规模验证。
  • 真实世界单中心数据,cutoff的普适性有待确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Data on the association between chimeric antigen receptor (CAR)-T-cell kinetics and patient outcome in the nontrial setting are missing, mainly due to the lack of broadly available CAR-T-cell diagnostic quantification tools. We performed prospective quantification of axicabtagene ciloleucel (axi-cel) in 21 patients treated for aggressive B-cell lymphoma at our clinic. Median peak CAR-T-cell count was 16.14 CAR-T cells/µL. Patients with 16.14/μL or higher peak CAR-T cells (strong expanders) had more day-30 objective responses (91% vs 40%, P = .02). In univariate analysis, peak CAR-T cell ≥ 16.14 (P < .001), normal platelet counts at start of lymphodepletion (P < .001), no prior stem cell transplant (P = .04), and peak CAR-T cells as continuous variable (P = .03) were associated with better progression-free survival (PFS). After adjusting for platelet counts and prior stem cell transplantation, peak CAR-T cells below median was still associated with shorter PFS (relative risk, 0.15, 95% confidence interval, 0.04-0.59, P = .007). Low platelet counts also maintained significant impact on PFS. Our data demonstrate association of axi-cel levels and outcome in a nontrial setting and for the first time use a cutoff to segregate weak and strong expanders with respective outcomes.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ayuk FA, Berger C, Badbaran A, et al. Axicabtagene ciloleucel in vivo expansion and treatment outcome in aggressive B-cell lymphoma in a real-world setting. Blood Adv. 2021. PMID: 34100900. doi:10.1182/bloodadvances.2020003959

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。